Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology. 2014 Jul; 60(1):12-4.
View in:
PubMed
subject areas
Drug Costs
Hepacivirus
Hepatitis C, Chronic
Heterocyclic Compounds, 3-Ring
Humans
Ribavirin
Simeprevir
Sofosbuvir
Sulfonamides
Uridine Monophosphate
authors with profiles
Mai Tuyet Pho